Mochi Health vs Ro: Flat-Rate Compounded Specialist vs Multi-Vertical Incumbent
Mochi Health and Ro overlap on cash-pay compounded GLP-1 but solve different problems. Ro is the multi-vertical incumbent with branded Wegovy/Zepbound through an insurance concierge plus compounded options, BBB-accredited B since 2018, and the largest user base in our cohort. Mochi is a compounded-only specialist with flat-rate dose-independent pricing and a strong consumer-experience signal, but with a Washington State Notice of Immediate Jeopardy on its affiliated compounding pharmacy and two active manufacturer lawsuits. The choice depends on whether you have insurance and how you weigh Mochi's substantiated pharmacy enforcement.
Mochi Health
2.8Flat-rate compounded GLP-1 with a vertically-integrated pharmacy under active state and federal scrutiny
Ro
3.6Established multi-vertical telehealth with insurance concierge for branded GLP-1
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
Ro for almost every reader. With commercial insurance covering Wegovy or Zepbound, Ro's insurance concierge can drop your effective monthly cost to $0-$25, math Mochi cannot match. For cash-pay users, Ro's BBB-accredited B-since-2018 trust posture is meaningfully cleaner than Mochi's pharmacy enforcement plus two-lawsuit stack. Choose Mochi only if flat-rate dose-independent pricing on compounded GLP-1 is specifically the binding need AND you've read the WA State enforcement record on Aequita and decided you're comfortable.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
Insurance pathway for branded GLP-1
Winner: RoRo runs a mature insurance concierge for branded Wegovy and Zepbound that can drop effective monthly cost to $0-$25 for users with eligible commercial coverage and a manufacturer savings card. Mochi is built around cash-pay compounded medication and does not run a comparable branded-insurance pathway.
Pharmacy-quality regulatory record
Winner: RoRo has no FDA enforcement actions on the GLP-1 line and no state pharmacy enforcement. Mochi's affiliated Aequita Pharmacy received a Washington State Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed-worker sterile compounding and improper cold-chain shipping. Ro is flagged for the April 2025 industry-wide FDA finasteride alert (different product line), which is a meaningfully softer counterweight than substantiated state enforcement.
BBB rating and accreditation tenure
Winner: RoRo is BBB Accredited with a B rating since July 2018, the longest BBB tenure in our compounded-GLP-1 cohort. Mochi is NOT BBB-accredited with complaints concentrated on cancellation and refund issues. Long-tenured BBB accreditation is a meaningful complaint-handling signal that Mochi has not earned.
Manufacturer lawsuit posture
Winner: RoMochi has two active federal lawsuits including the Novo corporate-practice-of-medicine claim. Ro has no comparable open manufacturer litigation. The Mochi lawsuit stack is one of the heaviest in our cohort.
Multi-vertical platform breadth
Winner: RoRo covers weight loss, men's health, hair loss, fertility, and skincare under one membership model with operations going back to 2017. Mochi is GLP-1-focused (compounded only). If you want one provider for multiple needs, Ro is the obviously broader option.
Customer service review signals
Winner: Mochi HealthMochi has Trustpilot 4.4/5 across roughly 15,600+ reviews (the largest sample in our compounded cohort) with no fraud notice. Ro has Trustpilot 3.7/5 across roughly 3,200 reviews and the largest ConsumerAffairs sample (4.4/5 across roughly 21,800 reviews). Mochi wins on Trustpilot specifically; Ro's larger ConsumerAffairs sample tips a different platform. Read both yourself if customer-service signal weight matters to you.
Flat-rate dose-independent pricing
Winner: Mochi HealthMochi's $99/mo semaglutide and $199/mo tirzepatide at every dose tier is the most innovative pricing model in our compounded cohort. Ro's pricing escalates with dose at typical cohort rates plus a $145/month membership. For cash-pay users on max-dose protocols, Mochi wins on titration economics; for cash-pay users at lower doses or users with insurance covering branded GLP-1, the comparison flips.
Operational maturity
Winner: RoRo's 2017 founding and multi-vertical scale gives it the largest user base in our cohort. Mochi is a younger entrant with smaller scale and substantial recent regulatory friction. For risk-averse users, Ro's operational depth is a meaningful advantage.
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
Ro: $45 first month, $145/mo standard or $74/mo annual prepay, plus medication. With insurance covering Wegovy or Zepbound and a Novo Nordisk savings card, branded path can land at $0-$25/mo effective cost. Without insurance, cash-pay compounded GLP-1 through Ro is $200-$400/mo medication on top of membership. Mochi: $79/mo membership + $99/mo flat semaglutide or $199/mo flat tirzepatide ($178-$278/mo all-in, dose-independent). Decision rule: insurance covers Wegovy or Zepbound -> Ro; cash-pay on max-dose compounded protocols where flat-rate matters -> consider Mochi but read the Aequita enforcement record first.
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.